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Sclerotherapy for Varicose Veins
O’Hare JL, Stephens J, Parkin D, et al. Br J Surg 2010;97:650-6.
Conclusion: There are no differences between sclerotherapy results in
patients treated for truncal varices with foam sclerotherapy regardless of
whether compression therapy after the procedure is used for 1 or 5 days.
Summary: There are no data on the optimal bandaging regimen after
foam sclerotherapy for truncal varices. In Great Britain, 80% of the members
of the Vascular Society of Great Britain and Ireland responding to a
questionnaire, and who treated patients with sclerotherapy, indicated they
used compression bandages, and 90% subsequently used compression stock-
ings after compression bandaging. Duration of treatment ranged from 1 to
7 days for initial bandages, with compression stockings used for 7 to 14 days,
with some surgeons recommending compression stockings for up to 3
months. The authors sought to determine whether duration of bandaging
could be reduced after foam sclerotherapy for truncal varices.
Patients with primary uncomplicated varicose veins were randomized
after foam sclerotherapy treatment to wearing compression bandaging for
24 hours or 5 days. In each case after compression bandages were removed,
thromboembolism deterrent (TED) stockings then used for a total of 14
days of compression after foam sclerotherapy. The primary end point of the
study was the 6-week Aberdeen Varicose Vein Severity Score (AVVSS) and
Buford pain score. The study randomized 124 legs, of which 61 were
randomized to 24 hours of compression bandaging and 63 to 5 days of
compression bandaging. Venous occlusion rates at 6 weeks were 90% and
89%, respectfully (P  .842). There were no differences in phlebitis after 2
weeks (P  .445), skin discoloration after 6 weeks (46% vs 40%; P  .546).
There were no differences between groups in the AVVSS from baseline to 2
weeks (–0.29 vs –0.80; P  .717) or to 6 weeks (–5.89 vs –5.14; 95%
confidence interval [CI] for the difference, –3.29 to 1.8; P  .563). There
were also no differences between groups in changes in the Buford pain score
from baseline to 2 weeks (–9.04 vs –2.80, P  .248) or to 6 weeks (–17.32
vs –8.46; 95% CI for the difference, –19.06 to 1.33; P .088). Finally, the
two groups also did not demonstrate any differences in changes in the Short
Form-36 score from baseline to 6 weeks (2.02 vs. 1.74; P  .903).
Comment: Foam sclerotherapy is replacing liquid sclerotherapy as the
preferred method of sclerotherapy for patients with truncal varicosities.
Compression after treatment is essential to optimal results. However, as the
authors point out with respect to foam sclerotherapy, the optimal duration
of compression after treatment has not been adequately studied. This study
is good news for patients. Compression bandages are not comfortable, and
the results indicate that 24 hours of compressive bandaging, followed by a
TED stocking for a total of 2 weeks, is just as efficacious as 5 days of
compressive bandaging, followed by a TED stocking for a total of 2 weeks.
The study provides practical guidance for post-therapy bandaging of patients
undergoing foam sclerotherapy.
Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients
Undergoing Surgery for Critical Limb Ischemia
Burdess A, Nimmo AF, Garden OJ, et al. Ann Surg 2010;252:37-42.
Conclusion: Dual antiplatelet therapy of aspirin and clopidogrel com-
pared with aspirin alone in patients undergoing surgery for critical limb
ischemia reduces biomarkers of thrombosis without an increase in unaccept-
able bleeding.
Summary: Myocardial injury is common after vascular surgery, with
reported incidences of between 8% and 40%. In patients with vascular
disease, use of clopidogrel has a moderate additional secondary preventative
effect to that of aspirin for prevention of cardiovascular end points (Bhatt
DL, N Engl J Med 2006;354:1706-717 and Yusuf S, et al, N Engl J Med
2001:345:494-502). The authors reasoned that given the benefits of dual
antiplatelet therapy, it would be reasonable to postulate dual antiplatelet
therapy would be beneficial in patients undergoing vascular surgery. The
hypothesis was that perioperative dual antiplatelet therapy would improve
biomarkers of atherothrombosis in patients undergoing surgery for critical
limb ischemia without causing unacceptable bleeding. This was a double-
blind, randomized, controlled trial comprising 108 patients undergoing
amputation or infrainguinal revascularization for critical limb ischemia. All
patients were maintained on aspirin (75 mg daily) and then randomized to
clopidogrel (600 mg before surgery and 75 mg daily for 3 days) or placebo.
There were 50 patients in the clopidogrel group and 58 in the placebo
group. Myocardial injury was assessed by plasma troponin concentrations
and platelet activation assessed by flow cytometry.
Platelet-monocyte aggregation before surgery was reduced by clopi-
dogrel (38%-30%; P .007). This reduction was retained postoperatively (P
 .0019). Postoperatively, there were 18 troponin events, 8 (16%) in the
clopidogrel group vs 10 (17.2%) in the placebo group (relatively risk [RR]
0.93, 95% confidence interval [CI], 0.39-2.17, P  .86). Half of the
troponin-positive events occurred preoperatively. Clopidogrel was associ-
ated with a greater decline in troponin concentrations (P  .001). Blood
transfusions were increased in the clopidogrel group (28% vs 12.6%; RR, 2.3;
95% CI, 1.0-5.29; P  .037). There was, however, no increase in majorlife-threatening bleeding (RR, 1.4; 95% CI, 0.49-3.76; P  .56) or minor
bleeding (RR, 1.64; 95% CI, 0.87-3.1; P  .12).
Comment: This is the first double blind, randomized trial of periop-
erative dual antiplatelet therapy in patients undergoing surgery for critical
limb ischemia. The study was underpowered to detect a difference in clinical
events; however, the authors were able to demonstrate improvements in
biomarkers of platelet activation without an increase in bleeding complica-
tions. Many troponin-positive events occurred before surgery. This suggests
“silent” preoperative myocardial injury is common in patients with critical
limb ischemia. The study indicates potential benefits of dual antiplatelet
therapy in the perioperative period in patients with critical limb ischemia.
Whether improvements in surrogate biomarkers translate to clinical benefit
remains to be established.
Risk of Recurrent Venous Thrombosis in Homozygous Carriers and
Double Heterozygous Carriers of Factor V Leiden and Prothrombin
G20210A
LijferingWM,Middeldorp S, Veeger NJ, et al. Circulation 2010;121:1706-
12.
Conclusion: Patients with venous thromboses who are homozygous
for factor V Leiden and/or prothrombin G20210A or are double heterozy-
gous carriers of factor V Leiden and prothrombin G20210, do not have a
high risk of recurrent venous thrombosis.
Summary: Within the Caucasian population, factor V Leiden has a
prevalence of approximately 5% and the prothrombin G20210A mutation
has a prevalence of approximately 2%. The risk for initial venous thrombosis
is clearly higher in heterozygote and homozygote carriers of factor V Leiden
and prothrombin G20210A. Heterozygote carriers of factor V Leiden have
an approximately a 5-fold increased risk for initial venous thrombosis,
whereas homozygote carriers have an 18-fold increased risk for initial venous
thrombosis. Individuals heterozygous for both factor V Leiden and pro-
thrombin G20210A have approximately a 20-fold risk for initial venous
thrombosis. It is generally assumed that patients with thrombophilia on the
bases of factor V Leiden and/or prothrombin G20210A mutations would
also have increased risk for recurrent venous thrombosis. This assumes the
risk of recurrence is driven primarily by the same factors that prompted the
initial venous thrombosis. However, some studies have suggested thrombo-
philia secondary to factor V Leiden and prothrombin G20210A mutations
actually do not increase the risk of recurrent venous thrombosis. This would
argue against testing for these genetic defects in individuals with an unpro-
voked first-time venous thrombosis (Christansen SC et al, JAMA 2005;293;
2352-61; and Baglin T et al, Lancet 2003;362:523-6).
The authors performed a case-control study using a large cohort of
families with thrombophilia identified through three major university hos-
pitals in the Netherlands. The goal was to calculate the risk of recurrent
venous thrombosis in individuals with homozygosity or double heterozy-
gosity of factor V Leiden and/or prothrombin G20210A. Controls were
patients with only one episode of venous thrombosis, and cases were
individuals with recurrent venous thrombosis. There were 788 individuals in
the cohort with venous thrombosis: 357 had factor V Leiden, and 137 had
prothrombin G20210A mutation, 27 had factor V Leiden and/or pro-
thrombin G20210A homozygosity, and 49 were double heterozygotes for
bothmutations. The cohort comprised 463 “controls” with only one venous
thrombosis and 325 “cases” with recurrent venous thrombosis. Compared
with noncarriers, the crude odds ratio for recurrence was 1.2 (95% confi-
dence interval [CI], 0.9-1.6) for heterozygote carriers of factor V Leiden,
0.7 (95% CI, 0.4-1.2) for prothrombin G20210A, 1.2 (95% CI, 0.5-2.6) for
homozygous carriers of factor V Leiden and/or prothrombin G20210A,
and 1.0 (95% CI, 0.6-1.9) for double heterozygous of both mutations. Risk
estimates were not altered by adjustments for family status, sex, age, other
natural anticoagulant deficiencies, or first event type.
Comment: The study has major indications for the evaluation of
patients with a first-time unprovoked venous thrombosis. It suggests evalu-
ation for factor V Leiden and prothrombin G20210A mutations have little
clinical implication or benefit for the individual with a first-time venous
thrombosis. If recurrence of first-time venous thrombosis is not increased by
the presence of these mutations, then there is no need to test for them in the
patient with an initial unprovoked venous thrombosis. The information in
this study does not apply to individuals with multiple recurrent venous
thrombi. It is also important to consider, because these mutations are
genetic, whether it is still reasonable to perform thrombophilia testing in the
patients with first-time venous thrombosis so that family members can be
appropriately counseled.
Superficial Venous Thrombosis and Venous Thromboembolism A
Large, Prospective Epidemiologic Study
Decousus H, Quere I, Presles E; Prospective Observational Superficial
Thrombophlebitis Study Group. Ann Intern Med 2010;152:218-24.Conclusion: A substantial number of patients with superficial venous
thrombosis (SVT) have venous thromboembolism (VTE) at presentation.
